Risk of significant liver enzyme elevation after switching antithyroid drugs
Authors' conclusion
These findings demonstrate that significant liver injury after ATD switching is frequent but not inevitable and occurs at comparable rates across switch groups, underscoring the need for close biochemical monitoring and individualized treatment decisions.
Study context
- Population
- Patients with hyperthyroidism who initiated MMI or propylthiouracil (PTU), developed significant liver enzyme elevation within 4 months, and switched to the alternate ATD within 12 months
- Participants
- 276 vs 82
- Exposure
- Switch from MMI to PTU vs switch from PTU to MMI after significant liver enzyme elevation
- MMI to PTUn = 276
- PTU to MMIn = 82
- Outcome
- Significant liver enzyme elevation after switching
- Follow-up
- 120 days following the second prescription
Methodological detailsTriNetX
- TriNetX
Main finding
As reported in the abstract
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk of significant liver enzyme elevation after switching antithyroid drugs. Eur J Endocrinol. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →